Compare Kinder Morgan Inc (KMI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs TransMedics Group Inc — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Kinder Morgan Inc is far larger — about 26.2× TransMedics Group Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and TransMedics Group Inc for 24 Days on average.
| KMI | TMDX | |
|---|---|---|
Market Cap | $71.81B | $2.74B |
Volume | 16,921,908 | 949,331 |
Sector | Energy | Health |
52-Week High | $34.31 | $150.42 |
52-Week Low | $25.84 | $61.99 |
Typical Hold Time | 150 Days | 24 Days |
Enterprise Value | $103.86B | $3.13B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, posting 18% net income margin growth in 2025. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6-7B growth runway from Southeast gas demand and data center expansion.
KMI offers investors stable fee-based revenue from energy infrastructure with a compelling dividend yield. The stock presents growth potential from natural gas demand trends but faces risks from energy market volatility and high debt levels. Current valuation metrics appear reasonable given the company's profitability and growth backlog, though technical indicators show some overbought conditions near-term.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
